On January 4, 2023 RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, reported that the United States Patent and Trademark Office (USPTO) has issued two patents related to the Company’s lead clinical asset, RYZ101, which uses 225Ac-DOTATATE to treat somatostatin receptor-positive (SSTR+) tumors (Press release, RayzeBio, JAN 4, 2023, View Source [SID1234625849]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The USPTO has issued U.S. Patent No. 11,497,822 and U.S. Patent No. 11,541,134, which are directed to compositions that include 225Ac-DOTATATE and the use of these compositions to treat SSTR+ neuroendocrine tumors, respectively. Both patents are valid until 2042, without taking into account any potential patent term extension.
"RYZ101 is currently being evaluated in two clinical trials and is poised to be the first Ac225 based radiopharmaceutical drug for the industry," said Ken Song, M.D., President and CEO of RayzeBio. "The recognition by the USPTO of our proprietary work with 225Ac-DOTATATE provides us valuable patent protection for the substantive investment we are making to bring forth this medicine to treat cancer patients."
About RYZ101
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. Details of the study can be found at View Source